19 studies found for:    ch14.18
Show Display Options
Rank Status Study
1 Completed ch14.18/CHO Bridging Study
Condition: Neuroblastoma
Intervention: Drug: ch14.18/CHO
2 Recruiting CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
Condition: Neuroblastoma Recurrent
Intervention: Drug: ch14.18/CHO
3 Unknown  Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Condition: Neuroblastoma
Interventions: Drug: ch14.18/CHO;   Drug: Aldesleukin;   Drug: Isotretinoin
4 Recruiting Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: dinutuximab beta
5 Completed
Has Results
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Biological: Aldesleukin;   Other: Diagnostic Laboratory Biomarker Analysis;   Biological: Dinutuximab;   Drug: Isotretinoin;   Biological: Sargramostim
6 Completed Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neurotoxicity Syndrome;   Pain;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Pharmacological Study
7 Not yet recruiting Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
Condition: Neuroblastoma
Interventions: Drug: Ch14.18;   Biological: NK Cells;   Drug: Lenalidomide
8 Completed Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma
Interventions: Biological: monoclonal antibody Ch14.18;   Drug: isotretinoin;   Biological: aldesleukin;   Biological: sargramostim
9 Completed
Has Results
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI;   Biological: ch14.18-UTC;   Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Biological: Aldesleukin (IL-2);   Drug: Isotretinoin
10 Recruiting High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)
Condition: Neuroblastoma
Interventions: Drug: Vincristine;   Drug: Aldesleukin;   Drug: ch14.18/CHO;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Busulfan;   Drug: Melphalan
11 Recruiting Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Stage 4 Neuroblastoma
Interventions: Biological: Dinutuximab;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
12 Active, not recruiting Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Biological: Aldesleukin;   Biological: Dinutuximab;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Biological: Sargramostim
13 Recruiting Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Conditions: Metastatic Malignant Neoplasm in the Lung;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
Interventions: Biological: Dinutuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Sargramostim
14 Recruiting Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Conditions: Ganglioneuroblastoma;   Recurrent Neuroblastoma
Interventions: Biological: Dinutuximab;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Sargramostim;   Drug: Temozolomide;   Drug: Temsirolimus
15 Not yet recruiting Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Conditions: Neuroblastoma;   Neoplasm, Residual;   Effects of Immunotherapy
Intervention: Drug: Dinutuximab. Immunotherapy
16 Recruiting NB2013-HR German (GPOH) / Dutch (DCOG) Trial
Condition: Neuroblastoma
Interventions: Drug: antibody ch14.18;   Drug: GM-CSF;   Drug: IL-2 i.v.;   Drug: IL-2 s.c.;   Drug: Retinoic acid
17 Unknown  Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: filgrastim;   Biological: monoclonal antibody Ch14.18;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: isotretinoin;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: bone marrow ablation with stem cell support;   Procedure: conventional surgery;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
18 Recruiting Therapy for Children With Advanced Stage Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
19 Recruiting High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Carboplatin;   Biological: Autologous stem cell infusion;   Biological: Granulocyte colony stimulating factor;   Radiation: Radiation therapy;   Drug: Isotretinoin (13-cis-retinoic acid);   Drug: Melphalan;   Drug: Etoposide

Indicates status has not been verified in more than two years